USPTO serial 79209028
MULTIBODY
Reviewed by CopyMark Law Group
Reg. 5450600Status 709
- Filing date
- Status date
- Registration date
- Apr 24, 2018
- Examiner
- JACKSON, STEVEN W
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with MULTIBODY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Cambridge, Cambridgeshire, GB
Cambridge, Cambridgeshire, GB
Cambridge, Cambridgeshire, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christopher J. Schulte
Christopher J. Schulte Merchant & Gould P.C.P.O. Box 2910Minneapolis, MN 55402-0910UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry and science; chemicals for laboratory research purposes; monoclonal antibodies and antibody fragments for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes; monoclonal antibody reagents for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes for use in the manufacture of therapeutic products | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; monoclonal antibodies for therapeutic purposes, namely, therapeutic agents for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the manufacture of therapeutic products | SECTION 71 - CANCELLED | — |
| 040 | Treatment and transformation of materials, namely, custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments | SECTION 71 - CANCELLED | — |
| 042 | Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory services relating to antibodies and antibody fragments; research and development in the field of antibodies and antibody fragments; medical research laboratory services relating to antibodies and antibody fragments; engineering of antibodies and antibody fragments; scientific research relating to the discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named MULTIBODY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 22, 2026 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Dec 30, 2025 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Dec 30, 2025 | INPC | INVALIDATION PROCESSED | — |
| Jul 8, 2025 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jun 3, 2025 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Nov 8, 2024 | C71T | CANCELLED SECTION 71 | — |
| Nov 8, 2024 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Oct 27, 2023 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Aug 19, 2023 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Apr 24, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Sep 7, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 9, 2018 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 9, 2018 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 24, 2018 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 24, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 6, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 1, 2018 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 1, 2018 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 17, 2018 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 28, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 21, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 21, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 19, 2017 | ALIE | ASSIGNED TO LIE | — |
| Dec 12, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 7, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 14, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 23, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 22, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 14, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 13, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 9, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 6, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 5, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 1, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |